Animal model of brain tumor and manufacturing method of animal model

Jeong Eun Lee, Daejeon (KR); Jeong Ho Lee, Daejeon (KR); Joo Ho Lee, Daejeon (KR); Seok Gu Kang, Suwon-si (KR)

USPTO: us-12667088 · published 2026-06-30 · patents · A01K 67/0276· A01K 2217/075· A01K 2217/15· A01K 2227/105· A01K 2267/0331

Animal model of brain tumor and manufacturing method of animal model

Seok Gu Kang, Suwon-si (KR) , Jeong Ho Lee, Daejeon (KR) , Joo Ho Lee, Daejeon (KR) , Jeong Eun Lee, Daejeon (KR) This is my paper

Pith reviewed 2026-07-01 23:31 UTC · model grok-4.3

classification patents A01K 67/0276A01K 2217/075A01K 2217/15A01K 2227/105A01K 2267/0331

keywords transgenic mouseglioblastomasubventricular zonep53PtenEGFRbrain tumor modelanimal model

0 comments

The pith

A transgenic mouse with p53 and Pten knockouts plus EGFR activation in SVZ stem cells develops glioblastoma in the dorsolateral-caudal cortex from GFAP positive cells with normal cytoarchitecture.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper presents a transgenic mouse engineered with knock-out mutations of p53 and Pten genes along with an activating mutation of the EGFR gene, all restricted to nerve stem cells of the subventricular zone. This produces glioblastoma specifically in the dorsolateral-caudal cortex region. The tumors arise from GFAP-positive nerve stem cells that keep normal cytoarchitecture. A sympathetic reader would care because the model supplies a tool to examine brain tumor origins and growth while the initiating cells retain their usual structure.

Core claim

The transgenic mouse comprises knock-out mutations of p53 and Pten genes in nerve stem cells of subventricular zone (SVZ), and an activating mutation of epidermal growth factor receptor (EGFR) gene in nerve stem cells of SVZ, wherein a glioblastoma occurs in the dorsolateral-caudal cortex region, wherein the glioblastoma develops from nerve stem cells that are positive for Glial fibrillary acidic protein (GFAP), wherein the GFAP positive nerve stem cells have normal cytoarchitecture.

What carries the argument

The transgenic mouse with targeted knock-out mutations of p53 and Pten plus EGFR activation restricted to SVZ nerve stem cells, which produces glioblastoma in the dorsolateral-caudal cortex from GFAP-positive cells that retain normal cytoarchitecture.

If this is right

Glioblastoma forms in the dorsolateral-caudal cortex region.
The tumor develops from GFAP-positive nerve stem cells.
These GFAP-positive cells maintain normal cytoarchitecture.
The phenotype is produced by the listed mutations applied to SVZ stem cells.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

The model indicates SVZ stem cells can serve as a source for cortical glioblastomas when these mutations are introduced.
Preservation of normal cytoarchitecture in the originating cells may allow more accurate examination of how tumors interact with surrounding brain tissue.
The approach could be adapted to test additional mutations or factors that influence whether tumors stay localized or spread.

Load-bearing premise

The specific combination of mutations restricted to SVZ nerve stem cells is sufficient to produce the described glioblastoma phenotype with the stated cellular origin and cytoarchitecture properties.

What would settle it

Observation that glioblastoma fails to form in the dorsolateral-caudal cortex or does not originate from GFAP-positive SVZ cells with normal cytoarchitecture would falsify the claim.

read the original abstract

1 . A transgenic mouse comprising, knock-out mutations of p53 and Pten genes in nerve stem cells of subventricular zone (SVZ), and an activating mutation of epidermal growth factor receptor (EGFR) gene in nerve stem cells of SVZ, wherein a glioblastoma occurs in the dorsolateral-caudal cortex region, wherein the glioblastoma develops from nerve stem cells that are positive for Glial fibrillary acidic protein (GFAP), wherein the GFAP positive nerve stem cells have normal cytoarchitecture.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Desk Editor's Note private letter to a colleague

Patent claims a glioblastoma mouse from SVZ-restricted p53/Pten/EGFR mutations but supplies no data, methods, or validation at all.

read the letter

This is a US patent that asserts a transgenic mouse with p53 and Pten knockouts plus EGFR activation limited to subventricular zone stem cells will produce glioblastoma specifically in the dorsolateral-caudal cortex, arising from GFAP-positive cells that retain normal cytoarchitecture. That is the entire content available.

The mutations themselves are standard in existing glioma models, so the only potential distinction is the claimed regional restriction and the preserved cytoarchitecture detail. Nothing in the document shows how the model is made, what histology or lineage tracing was done, or any phenotypic data to support the location or cellular origin claims.

The obvious limitation is the total absence of evidence. Patents are written as assertions rather than results, which is fine for legal protection but leaves the scientific claim untestable from the text. No prior literature is engaged or reduced, and no experiments are described.

This document is useful only to patent attorneys or groups filing on animal models for IP reasons. It has no value for researchers seeking reproducible findings or new mechanistic insight. I would not bring it to a reading group, would not cite it in scientific work, and would not send it for peer review as research because there is no research presented to review.

Referee Report

1 major / 0 minor

Summary. The manuscript is a patent claim describing a transgenic mouse with knock-out mutations of p53 and Pten plus an activating EGFR mutation, all restricted to nerve stem cells of the subventricular zone (SVZ). It asserts that this produces glioblastoma specifically in the dorsolateral-caudal cortex, arising from GFAP-positive nerve stem cells that retain normal cytoarchitecture.

Significance. If the asserted phenotype were experimentally validated, the model could provide a targeted system for studying glioblastoma initiation from SVZ stem cells and the sufficiency of these three genetic alterations. The manuscript supplies no data, methods, histology, or validation, so the significance cannot be assessed from the provided text.

major comments (1)

[Abstract/Claim 1] Abstract/Claim 1: The central claim that SVZ-restricted p53/Pten knock-out plus EGFR activation is sufficient to generate glioblastoma in the dorsolateral-caudal cortex from GFAP+ cells with normal cytoarchitecture is stated without any supporting experimental results, animal-generation protocol, lineage-tracing data, or phenotypic characterization. This renders the sufficiency assertion untestable on the basis of the manuscript.

Simulated Author's Rebuttal

1 responses · 0 unresolved

We thank the referee for reviewing the manuscript. This document is a patent application describing an animal model and its manufacturing method rather than a research article presenting experimental results. We respond to the major comment below.

read point-by-point responses

Referee: [Abstract/Claim 1] Abstract/Claim 1: The central claim that SVZ-restricted p53/Pten knock-out plus EGFR activation is sufficient to generate glioblastoma in the dorsolateral-caudal cortex from GFAP+ cells with normal cytoarchitecture is stated without any supporting experimental results, animal-generation protocol, lineage-tracing data, or phenotypic characterization. This renders the sufficiency assertion untestable on the basis of the manuscript.

Authors: The manuscript is a patent application whose primary purpose is to claim the transgenic mouse model and the method for its manufacture. Patent claims of this type describe the invention and its intended properties without including the full experimental datasets, histology, or validation results that would be expected in a peer-reviewed research paper. The full text of the application provides the manufacturing method for generating the described transgenic mouse. The sufficiency of the genetic alterations for producing the stated phenotype is part of the inventive claim; reproduction and validation would be performed by those practicing the invention. We do not claim to have supplied the experimental characterization that a scientific paper would require. revision: no

Circularity Check

0 steps flagged

No circularity: patent is a descriptive claim with no derivations or predictions

full rationale

The document consists solely of a single claim asserting a transgenic mouse phenotype from SVZ-restricted mutations. No equations, fitted parameters, predictions, self-citations, or derivation steps are present. The claim is an invention disclosure, not a chain of reasoning that could reduce to its inputs by construction. This matches the default expectation of no significant circularity for non-derivational documents.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

This is a patent for a genetic engineering method and claimed phenotype. It contains no mathematical derivations, fitted parameters, or scientific axioms. The content is an applied invention description rather than an analysis resting on upstream assumptions.

pith-pipeline@v0.9.1-grok · 5672 in / 1198 out tokens · 26132 ms · 2026-07-01T23:31:02.491223+00:00 · methodology

discussion (0)

Lean theorems connected to this paper

Citations machine-checked in the Pith Canon. Every link opens the source theorem in the public Lean library.

IndisputableMonolith/Foundation/RealityFromDistinction.lean reality_from_one_distinction unclear

?

unclear
Relation between the paper passage and the cited Recognition theorem.

A transgenic mouse comprising knock-out mutations of p53 and Pten genes in nerve stem cells of subventricular zone (SVZ), and an activating mutation of epidermal growth factor receptor (EGFR) gene in nerve stem cells of SVZ, wherein a glioblastoma occurs in the dorsolateral-caudal cortex region...

What do these tags mean?

matches: The paper's claim is directly supported by a theorem in the formal canon.
supports: The theorem supports part of the paper's argument, but the paper may add assumptions or extra steps.
extends: The paper goes beyond the formal theorem; the theorem is a base layer rather than the whole result.
uses: The paper appears to rely on the theorem as machinery.
contradicts: The paper's claim conflicts with a theorem or certificate in the canon.
unclear: Pith found a possible connection, but the passage is too broad, indirect, or ambiguous to say the theorem truly supports the claim.